The adeno-to-neuroendocrine transition in PCa can result in resistance to targeted therapies, analysis of genetically engineered mouse PCa samples using single-cell multiplexed genomics reveals that Foxa2 regulates this transition pattern and activates the KIT pathway to promote tumor growth in both mouse and human NEPC, which offers a potential strategy for the treatment of castration-resistant NEPC (Han et al. 2022). Here, KIT is linked to posterior cortical atrophy.